SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Gluud Maria)
 

Sökning: WFRF:(Gluud Maria) > Long-term outcomes ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007661naa a2200925 4500
001oai:DiVA.org:liu-184375
003SwePub
008220421s2022 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:149187043
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1843752 URI
0247 a https://doi.org/10.1007/s00134-022-06677-22 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1491870432 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Granholm, Andersu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
2451 0a Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
264 c 2022-03-31
264 1b SPRINGER,c 2022
338 a print2 rdacarrier
500 a Funding Agencies|Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited; Research Council of Rigshospitalet [0062998, E-22703-06]
520 a Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22). Conclusion Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng
653 a COVID-19; Hypoxaemia; Critical illness; Corticosteroids; Quality of life; Mortality
7001 a Kjaer, Maj-Brit Norregaardu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Munch, Marie Warreru Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Myatra, Sheila Nainanu Tata Mem Hosp, India4 aut
7001 a Vijayaraghavan, Bharath Kumar Tirupakuzhiu Apollo Hosp, India; Chennai Crit Care Consultants, India; George Inst Global Hlth, India4 aut
7001 a Cronhjort, Mariau Karolinska Institutet,Karolinska Inst, Sweden4 aut
7001 a Wahlin, Rebecka Rubensonu Karolinska Institutet,Karolinska Inst, Sweden4 aut
7001 a Jakob, Stephan M.u Univ Bern, Switzerland4 aut
7001 a Cioccari, Lucau Univ Bern, Switzerland4 aut
7001 a Vesterlund, Gitte Kingou Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Meyhoff, Tine Sylvestu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Helleberg, Marieu Copenhagen Univ Hosp, Denmark4 aut
7001 a Moller, Morten Hylanderu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut
7001 a Benfield, Thomasu Copenhagen Univ Hosp Amager & Hvidovre, Denmark4 aut
7001 a Venkatesh, Balasubramanianu Univ New South Wales, Australia4 aut
7001 a Hammond, Naomi E.u Univ New South Wales, Australia; Royal North Shore Hosp, Australia4 aut
7001 a Chew, Michelle S,d 1969-u Linköpings universitet,Avdelningen för klinisk kemi och farmakologi,Medicinska fakulteten,Region Östergötland, ANOPIVA US4 aut0 (Swepub:liu)micch61
7001 a Bassi, Abhinavu Chennai Crit Care Consultants, India4 aut
7001 a John, Oommenu Chennai Crit Care Consultants, India; Manipal Acad Higher Educ, India4 aut
7001 a Jha, Vivekanandu Chennai Crit Care Consultants, India; Manipal Acad Higher Educ, India; Imperial Coll London, England4 aut
7001 a Kristiansen, Klaus Tjelleu Univ Copenhagen, Denmark4 aut
7001 a Ulrik, Charlotte Suppliu Univ Copenhagen, Denmark4 aut
7001 a Jorgensen, Vibeke Lindu Copenhagen Univ Hosp, Denmark4 aut
7001 a Smitt, Margitu Copenhagen Univ Hosp, Denmark4 aut
7001 a Bestle, Morten H.u Copenhagen Univ Hosp North Zealand, Denmark; Univ Copenhagen, Denmark4 aut
7001 a Andreasen, Anne Sofieu Copenhagen Univ Hosp Herlev, Denmark4 aut
7001 a Poulsen, Lone Musaeusu Zealand Univ Hosp, Denmark4 aut
7001 a Rasmussen, Bodil Steenu Collaborat Res Intens Care CRIC, Denmark; Aalborg Univ Hosp, Denmark4 aut
7001 a Brochner, Anne Craveirou Collaborat Res Intens Care CRIC, Denmark; Univ Hosp Southern Denmark, Denmark4 aut
7001 a Strom, Thomasu Odense Univ Hosp, Denmark; Univ Hosp Southern, Denmark4 aut
7001 a Moller, Andersu Naestved Slagelse Ringsted Hosp, Denmark4 aut
7001 a Khan, Mohd Saifu Rajendra Inst Med Sci, India4 aut
7001 a Padmanaban, Ajayu Apollo Hosp, India4 aut
7001 a Divatia, Jigeeshu Vasishthau Tata Mem Hosp, India4 aut
7001 a Saseedharan, Sanjithu SL Raheja Hosp, India,Sir HN Reliance Fdn Hosp & Res Ctr, India,Herning Hosp, Denmark4 aut
7001 a Borawake, Kapilu Vishwaraj Hosp, India4 aut
7001 a Kapadia, Farhadu Hinduja Hosp, India4 aut
7001 a Dixit, Subhalu Sanjeevan Hosp, India4 aut
7001 a Chawla, Rajeshu Indraprastha Apollo Hosp, India4 aut
7001 a Shukla, Urviu Symbiosis Univ Hosp & Res Ctr, India4 aut
7001 a Amin, Pravinu Bombay Hosp Inst Med Sci, India4 aut
7001 a Chew, Michelle S,d 1969-u Linköpings universitet,Avdelningen för klinisk kemi och farmakologi,Medicinska fakulteten,Region Östergötland, ANOPIVA US4 aut0 (Swepub:liu)micch61
7001 a Wamberg, Christian Aageu Bispebjerg Hosp, Denmark4 aut
7001 a Bose, Neetau Gotri Gen Hosp, India4 aut
7001 a Shah, Mehul S.u Sir HN Reliance Fdn Hosp & Res Ctr, India4 aut
7001 a Darfelt, Iben S.u Herning Hosp, Denmark4 aut
7001 a Gluud, Christianu Copenhagen Univ Hosp, Denmark; Univ Southern Denmark, Denmark4 aut
7001 a Lange, Theisu Univ Copenhagen, Denmark4 aut
7001 a Perner, Andersu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark; Univ New South Wales, Australia4 aut
7102 a Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmarkb Tata Mem Hosp, India4 org
7730 t Intensive Care Medicined : SPRINGERg 48, s. 580-589q 48<580-589x 0342-4642x 1432-1238
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-184375
8564 8u https://doi.org/10.1007/s00134-022-06677-2
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:149187043

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy